Rising Prevalence of Valvular Disorders and Advancements in Minimally Invasive Procedures Drive Growth in the Valvular Heart Disease Market

Valvular heart disease market was valued at $19.8 billion in 2024 and is projected to reach $64.5 billion by 2035, growing at a CAGR of 11.4% during the forecast period (2025–2035). Rising prevalence of valvular heart disorders, particularly among the ageing population, is driving demand for effective diagnosis and treatment options. Increasing awareness about heart valve diseases and the implementation of screening programs are enabling early detection, improving patient outcomes, and supporting wider adoption of therapies.

Browse the full report description of “Valvular Heart Diseases Market Size, Share & Trends Analysis Report by Product Type (Patches, Valves, Grafts, Medications, and Others) by Treatment Type (Medication, Surgery, and Others) by End User (Hospitals, Specialty Clinics, and Others) and by Valve Position Segmentation (Aortic Valve, Mitral Valve, and Tricuspid and Pulmonary Valves) and (Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/valvular-heart-diseases-treatment-market

Advancements in minimally invasive procedures and innovative treatment technologies, such as transcatheter interventions, are further accelerating market growth. These developments, combined with growing patient awareness and preventive healthcare initiatives, are expanding access to care and driving sustained growth in the valvular heart disease market.

Real-Life Incidents Highlight the Environmental Importance of Self-Driving Cars

• 2025: The Centers for Disease Control and Prevention (CDC) emphasized that enhanced awareness campaigns and routine screening programs have led to earlier detection of valvular disorders, enabling timely interventions and better clinical results.
• 2025: The American Heart Association (AHA) reported that valvular heart diseases affect over 5 million adults in the U.S., with prevalence increasing significantly among the elderly, highlighting the growing need for early diagnosis and treatment.
• 2024: According to MedTech Europe, technological innovations in diagnostic tools and valve repair/replacement devices are expanding treatment options, supporting increased adoption in hospitals and specialized cardiac care centers.

Industry Response

The valvular heart disease market is evolving rapidly with advancements in minimally invasive procedures, transcatheter interventions, and innovative valve repair and replacement technologies. Manufacturers are investing in research and development to enhance device safety, efficacy, and procedural outcomes, while expanding their presence across hospitals and cardiac care centers.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Product Type
• Treatment Type
• End User

• Competitive Landscape – Abbott Laboratories, Boston Scientific Corp., Edwards Lifesciences Corp., LivaNova Plc and Medtronic Plc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Valvular Heart Diseases Market Report Segment

By Product Type

• Patches
• Valves
• Grafts
• Medications
• Others

By Treatment Type

• Medication
• Surgery
• Others

By End User

• Hospitals
• Specialty Clinics
• Others

Global Valvular Heart Diseases Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/valvular-heart-diseases-treatment-market